MX2023005703A - Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo. - Google Patents
Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo.Info
- Publication number
- MX2023005703A MX2023005703A MX2023005703A MX2023005703A MX2023005703A MX 2023005703 A MX2023005703 A MX 2023005703A MX 2023005703 A MX2023005703 A MX 2023005703A MX 2023005703 A MX2023005703 A MX 2023005703A MX 2023005703 A MX2023005703 A MX 2023005703A
- Authority
- MX
- Mexico
- Prior art keywords
- salt
- containing compound
- same
- production intermediate
- novel nitrogen
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 6
- 150000003839 salts Chemical class 0.000 title abstract 5
- -1 nitrogen-containing compound Chemical class 0.000 title abstract 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000007112 amidation reaction Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/08—Copper compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a un método para manufacturar de manera eficiente un compuesto que contiene nitrógeno, el cual es usado para manufacturar un agente de tratamiento enfermedades que se refieren a integrina, o una sal del mismo y manufacturación de un intermediario del compuesto o una sal del mismo. Un método para manufacturar un compuesto novedoso que contiene nitrógeno o una sal del mismo incluye (1) una etapa de obtener un compuesto representado por la Fórmula [10] o una sal del mismo a través de una reacción de amidación; y (2) una etapa de desprotección del compuesto representado por la Fórmula [10] o una sal del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015062306 | 2015-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005703A true MX2023005703A (es) | 2023-05-29 |
Family
ID=56977546
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012184A MX2017012184A (es) | 2015-03-25 | 2016-03-25 | Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo. |
| MX2023005704A MX2023005704A (es) | 2015-03-25 | 2017-09-25 | Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo. |
| MX2023005703A MX2023005703A (es) | 2015-03-25 | 2017-09-25 | Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo. |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012184A MX2017012184A (es) | 2015-03-25 | 2016-03-25 | Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo. |
| MX2023005704A MX2023005704A (es) | 2015-03-25 | 2017-09-25 | Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo. |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20180008583A1 (es) |
| EP (3) | EP4059936A1 (es) |
| JP (1) | JP6411634B2 (es) |
| KR (1) | KR102029746B1 (es) |
| CN (2) | CN107428755B (es) |
| AU (4) | AU2016237099C1 (es) |
| BR (1) | BR112017020484B1 (es) |
| CA (1) | CA2980268C (es) |
| CO (1) | CO2017010806A2 (es) |
| CY (1) | CY1124387T1 (es) |
| DK (1) | DK3275883T3 (es) |
| ES (1) | ES2877707T3 (es) |
| HR (1) | HRP20211031T1 (es) |
| HU (1) | HUE059670T2 (es) |
| IL (4) | IL254532B (es) |
| LT (1) | LT3275883T (es) |
| MX (3) | MX2017012184A (es) |
| PL (1) | PL3275883T3 (es) |
| PT (1) | PT3275883T (es) |
| RS (1) | RS62165B1 (es) |
| RU (1) | RU2767398C2 (es) |
| SG (2) | SG10201902609TA (es) |
| SI (1) | SI3275883T1 (es) |
| SM (1) | SMT202100392T1 (es) |
| WO (1) | WO2016153054A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3929196B1 (en) | 2013-09-24 | 2023-08-23 | FUJIFILM Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
| EP3589627A4 (en) | 2017-02-28 | 2020-08-05 | Morphic Therapeutic, Inc. | (ALPHA-V) (BETA-6) INHIBITORS INTEGRIN |
| EP3760202A1 (en) | 2017-02-28 | 2021-01-06 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| EP3617206A1 (en) | 2018-08-29 | 2020-03-04 | Morphic Therapeutic, Inc. | Integrin inhibitors |
| PL3844162T3 (pl) | 2018-08-29 | 2025-06-09 | Morphic Therapeutic, Inc. | Inhibitory integryny alfa v beta 6 |
| TW202028179A (zh) * | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| JP7714466B2 (ja) * | 2019-03-11 | 2025-07-29 | バイオコンパティブルズ ユーケー リミテッド | 中枢神経系腫瘍の治療方法 |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| KR20230130610A (ko) * | 2020-10-14 | 2023-09-12 | 센테너리 인스티튜트 오브 캔서 메디신 앤드 셀 바이올로지 | 치료적 방사성 표지된 접합체 및 요법에서의 이의 용도 |
| JP2024500829A (ja) | 2020-12-21 | 2024-01-10 | アドヴァンスド アクセラレーター アプリケーションズ インターナショナル エセ．アー． | 治療診断剤として使用するための放射性標識α－Ｖβ－３及び／又はα－Ｖβ－５インテグリンアンタゴニスト |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5941386B2 (ja) | 1977-01-14 | 1984-10-06 | 株式会社紀文 | 高蛋白水産練製品様食品の製法 |
| DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| ES2270475T3 (es) | 1996-11-27 | 2007-04-01 | Bristol-Myers Squibb Pharma Company | Nuevos antagonistas de receptores de integrina. |
| GEP20032921B (en) * | 1997-12-17 | 2003-03-25 | Merck & Co Inc | Integrin Receptor Antagonists Pharmaceutical Compositions Containing the Same and Methods for Treatment |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| JP2002532440A (ja) | 1998-12-18 | 2002-10-02 | デュポン ファーマシューティカルズ カンパニー | ビトロネクチン受容体拮抗剤薬剤 |
| EP1140203B1 (en) * | 1998-12-18 | 2007-05-23 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals |
| JP2003520271A (ja) | 2000-01-24 | 2003-07-02 | メルク エンド カムパニー インコーポレーテッド | αｖインテグリン受容体拮抗薬 |
| AU7002501A (en) * | 2000-06-21 | 2002-01-02 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| ATE530183T1 (de) | 2001-01-29 | 2011-11-15 | Ortho Mcneil Pharm Inc | Substituierte indole und ihre verwendung als integrin-antagonisten |
| KR101383655B1 (ko) | 2010-05-24 | 2014-04-10 | 주식회사 바이오이미징코리아 | 트리카르보닐 테크네슘-99ｍ 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물 |
| FR2968999B1 (fr) * | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
| FR2980364B1 (fr) * | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
| WO2013048996A1 (en) | 2011-09-30 | 2013-04-04 | Ge Healthcare Limited | Method for the purification of a peptide-based imaging agent precursor |
| MX358311B (es) * | 2012-04-17 | 2018-08-14 | Fujifilm Corp | Compuesto heterociclico que contiene nitrogeno o sal del mismo. |
| FR3001154B1 (fr) * | 2013-01-23 | 2015-06-26 | Guerbet Sa | Magneto-emulsion vectorisee |
| EP3929196B1 (en) * | 2013-09-24 | 2023-08-23 | FUJIFILM Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
-
2016
- 2016-03-25 PT PT167689579T patent/PT3275883T/pt unknown
- 2016-03-25 EP EP22170836.5A patent/EP4059936A1/en not_active Withdrawn
- 2016-03-25 MX MX2017012184A patent/MX2017012184A/es unknown
- 2016-03-25 HR HRP20211031TT patent/HRP20211031T1/hr unknown
- 2016-03-25 WO PCT/JP2016/059729 patent/WO2016153054A1/ja not_active Ceased
- 2016-03-25 HU HUE16768957A patent/HUE059670T2/hu unknown
- 2016-03-25 JP JP2017508476A patent/JP6411634B2/ja active Active
- 2016-03-25 EP EP16768957.9A patent/EP3275883B1/en active Active
- 2016-03-25 CN CN201680018240.1A patent/CN107428755B/zh active Active
- 2016-03-25 DK DK16768957.9T patent/DK3275883T3/da active
- 2016-03-25 SG SG10201902609TA patent/SG10201902609TA/en unknown
- 2016-03-25 CA CA2980268A patent/CA2980268C/en active Active
- 2016-03-25 SI SI201631232T patent/SI3275883T1/sl unknown
- 2016-03-25 RU RU2020115068A patent/RU2767398C2/ru active
- 2016-03-25 LT LTEPPCT/JP2016/059729T patent/LT3275883T/lt unknown
- 2016-03-25 KR KR1020177026236A patent/KR102029746B1/ko active Active
- 2016-03-25 CN CN202010084360.XA patent/CN111171026B/zh active Active
- 2016-03-25 AU AU2016237099A patent/AU2016237099C1/en active Active
- 2016-03-25 BR BR112017020484-3A patent/BR112017020484B1/pt active IP Right Grant
- 2016-03-25 RS RS20210779A patent/RS62165B1/sr unknown
- 2016-03-25 PL PL16768957T patent/PL3275883T3/pl unknown
- 2016-03-25 SM SM20210392T patent/SMT202100392T1/it unknown
- 2016-03-25 ES ES16768957T patent/ES2877707T3/es active Active
- 2016-03-25 EP EP21168086.3A patent/EP3872079A1/en not_active Withdrawn
- 2016-03-25 SG SG11201707899SA patent/SG11201707899SA/en unknown
-
2017
- 2017-09-17 IL IL254532A patent/IL254532B/en unknown
- 2017-09-22 US US15/712,815 patent/US20180008583A1/en not_active Abandoned
- 2017-09-25 MX MX2023005704A patent/MX2023005704A/es unknown
- 2017-09-25 MX MX2023005703A patent/MX2023005703A/es unknown
- 2017-10-24 CO CONC2017/0010806A patent/CO2017010806A2/es unknown
-
2019
- 2019-10-10 AU AU2019246859A patent/AU2019246859B2/en active Active
-
2020
- 2020-09-29 US US17/037,103 patent/US20210015802A1/en not_active Abandoned
- 2020-10-02 AU AU2020244578A patent/AU2020244578B2/en active Active
- 2020-10-02 AU AU2020244580A patent/AU2020244580B2/en active Active
-
2021
- 2021-05-18 IL IL283224A patent/IL283224B/en unknown
- 2021-05-19 IL IL283288A patent/IL283288B/en unknown
- 2021-05-19 IL IL283289A patent/IL283289B/en unknown
- 2021-07-02 CY CY20211100591T patent/CY1124387T1/el unknown
-
2023
- 2023-02-21 US US18/112,423 patent/US20240108607A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005704A (es) | Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo. | |
| PH12016502334A1 (en) | Method for producing fused heterocyclic compound | |
| EP4635568A3 (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX353553B (es) | Metodo para producir derivados de 4,4-difluoro-3,4-dihidroisoquino lina. | |
| PH12018500582A1 (en) | Crosslinked nucleic acid guna, method for producing same, and intermediate compound | |
| MY192466A (en) | Processes for the preparation of an apoptosis-inducing agent | |
| MY169495A (en) | Pharmaceutical compositions | |
| MX342746B (es) | Derivados de mostaza de nitrogeno. | |
| MY191236A (en) | Diorganylphosphinic acid salts, method for the production thereof and the use thereof | |
| WO2015008218A3 (en) | Process for the preparation of suvorexant and intermediates useful in the synthesis of suvorexant | |
| MX2021005869A (es) | Derivado de dihidroindolizinona. | |
| MX2014006992A (es) | Disales de acido malonico y metodo para preparar dihaluros de malonilo. | |
| NZ736970A (en) | Process methods for phosphatidylinositol 3-kinase inhibitors | |
| ZA201805790B (en) | Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and "azd9291 aniline" or a salt thereof | |
| AR090566A1 (es) | Proceso para la produccion de inhibidores de crr | |
| MX385672B (es) | Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituida. | |
| SA518391413B1 (ar) | عملية تحضير وتبلر لليوزيمينول | |
| PH12016501704B1 (en) | Method for producing 2-acyliminopyridine derivative | |
| MY194792A (en) | Method for producing optically active 2-(2-fluorobiphenyl-4-yl) propanoic acid | |
| MX337997B (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
| MX2015015746A (es) | Proceso para la preparacion de arformoterol o sal del mismo. | |
| MX374777B (es) | Un proceso para la producción de complejos de caseína n-acetil-aspartilada de hierro (iii) y uso de los mismos en composiciones farmacéuticas. | |
| JO3276B1 (ar) | طريقة لتخليق 3، 4-داي ميثوكسي باي سيكلو [4. 2. 0] أوكتا-5،3،1-تراي إين-7-كربونيتريل واستخدامها لتخليق ايفابرادين والأملاح المضافة منه مع حمض مقبول صيدلانيا. | |
| MX2016005219A (es) | Tinturas acidas, proceso para su produccion y su uso. | |
| MX2016005220A (es) | Tinturas acidas, proceso para su produccion y su uso. |